title: The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer.
abstract: Given the association of deficient natural immunity with the risk of metastatic disease, the ability to activate natural killer cell function may have a therapeutic significance. The effect of continuous infusion of interleukin 2 plus intramuscular interferon alfa on natural immune status was, therefore, analyzed in eight patients with head and neck cancer. Also evaluated was the effect of interleukin 2-interferon alfa therapy on lymphokine-activated killer cell activity as well as total lymphocyte count, percent of lymphocyte subsets, and levels of both circulating immune complexes and antibody classes. Both the percent and absolute number of natural killer cells (ie, CD56+ CD3- lymphocytes) within peripheral blood as well as natural killer cell activity against K562 targets increased significantly with treatment. The remaining immune parameters were not significantly altered. The demonstrated capacity to modulate natural immune function supports the potential use of interleukin 2-containing regimens as a preventive measure against metastatic disease in patients with head and neck cancer.
authors.affiliation: Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: S P
authors.initials: SP
authors.lastname: Schantz
authors.forename: G
authors.initials: G
authors.lastname: Clayman
authors.forename: T
authors.initials: T
authors.lastname: Racz
authors.forename: E A
authors.initials: EA
authors.lastname: Grimm
authors.forename: F J
authors.initials: FJ
authors.lastname: Liu
authors.forename: P
authors.initials: P
authors.lastname: Lavedan
authors.forename: D
authors.initials: D
authors.lastname: Taylor
authors.forename: C
authors.initials: C
authors.lastname: Pellegrino
authors.forename: H
authors.initials: H
authors.lastname: Savage
mesh_terms: D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects; D007694:Killer Cells, Natural / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control
chemical_list: D000936:Antigen-Antibody Complex; D007370:Interferon Type I; D007376:Interleukin-2